Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ascites01:19

Ascites

DefinitionAscites is the buildup of fluid inside the peritoneal cavity. It occurs when fluid moves out of the vascular system faster than the peritoneal lymphatics can remove it. This fluid shift is most commonly seen in liver cirrhosis but can also appear in several other systemic disorders.EtiologyCirrhosis remains the leading cause of ascites. Other conditions that can contribute include:Heart failureConstrictive pericarditisAbdominal cancersNephrotic syndromeSevere protein–calorie...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Pemigatinib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2023
Same author

Epcoritamab: First Approval.

Drugs·2023
Same author

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023
Same author

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023

Related Experiment Video

Updated: May 21, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Catumaxomab: in malignant ascites.

James E Frampton1

  • 1Adis, Auckland, New Zealand. demail@adis.com

Drugs
|June 9, 2012
PubMed
Summary
This summary is machine-generated.

Catumaxomab combined with paracentesis significantly improves outcomes for patients with malignant ascites. This therapy prolongs survival and enhances quality of life in EpCAM-positive cancer patients resistant to chemotherapy.

More Related Videos

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Experiment Videos

Last Updated: May 21, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Therapeutics

Background:

  • Malignant ascites is a common complication in advanced cancers.
  • Current treatments like paracentesis offer only temporary relief.
  • Patients with EpCAM-positive tumors often develop resistance to conventional chemotherapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of catumaxomab in combination with paracentesis for malignant ascites.
  • To compare outcomes of catumaxomab plus paracentesis versus paracentesis alone.

Main Methods:

  • A randomized, open-label, multicenter, pivotal phase II/III trial.
  • Patients with recurrent symptomatic malignant ascites due to EpCAM-positive tumors were enrolled.
  • Treatment arms included paracentesis alone versus paracentesis followed by catumaxomab therapy.

Main Results:

  • Catumaxomab significantly prolonged paracentesis-free survival and time to repeat paracentesis.
  • Improved and sustained reduction in ascites signs and symptoms observed.
  • Delayed deterioration in health-related quality of life compared to paracentesis alone.
  • Benefits were consistent across various epithelial cancers and irrespective of antibody response.

Conclusions:

  • Catumaxomab in combination with paracentesis is an effective treatment for malignant ascites in EpCAM-positive cancer patients.
  • The therapy offers significant survival and quality-of-life benefits.
  • Catumaxomab was generally well-tolerated with manageable side effects.